Want to see FR:ALTHE full AI Analyst Report?
ALTHE Stock Chart & Stats
€0.59
<€0.01(<0.01%)
At close: 4:00 PM EDT
€0.59
<€0.01(<0.01%)
Day’s Range― - ―
52-Week Range€0.40 - €1.25
Previous CloseN/A
Volume57.25K
Average Volume (3M)82.89K
Market Cap
€42.47M
Enterprise Value€37.71
Total Cash (Recent Filing)€3.38M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Oct 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding73,123,314
10 Day Avg. Volume39,747
30 Day Avg. Volume82,891
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-13.53
Price to Sales (P/S)29.53
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Non-invasive HIFU Platform (Echopulse)Theraclion's focus on HIFU and the Echopulse imaging‑guided platform is a durable structural advantage: non‑invasive therapies are a sustained medical trend, and a differentiated device with imaging integration can support clinical adoption and recurring procedure demand over time.
Lean, Focused OrganizationA small, specialized team implies low fixed overhead and operational nimbleness, enabling concentrated R&D and faster iteration on device improvements. This organizational efficiency can extend runway per euro raised and ease partnerships for scale without heavy permanent cost increases.
Historical Revenue Growth PotentialReported historical revenue growth indicates underlying market demand or successful commercial traction in prior periods. If management can stabilize execution, this demonstrated ability to grow revenues is a durable indicator that the technology can expand adoption across physicians and clinics.
Bears Say
Structurally Negative ProfitabilityGross, operating and net losses across reported years show the company is structurally unprofitable. Persistent negative margins mean any recovery depends on material revenue scale or sustained cost reduction; absent that, profitability remains an unresolved long‑term risk to viability.
High Cash Burn And Negative Cash FlowConsistently negative operating and free cash flow, with ~-€7.2M outflow in 2025, indicates reliance on external financing to fund operations. Continued cash burn constrains investment in commercialization and raises dilution and financing risk over the medium term unless a path to self‑funding emerges.
Elevated Balance-sheet And Solvency RiskNegative equity and meaningful debt relative to a small revenue base signal weakened capital buffers and limited financial flexibility. This elevates solvency and refinancing risk, potentially increasing cost of capital and constraining strategic options if revenues do not scale quickly.
ALTHE FAQ
What was Theraclion SA’s price range in the past 12 months?
Theraclion SA lowest stock price was €0.40 and its highest was €1.25 in the past 12 months.
What is Theraclion SA’s market cap?
Theraclion SA’s market cap is €42.47M.
When is Theraclion SA’s upcoming earnings report date?
Theraclion SA’s upcoming earnings report date is Oct 14, 2026 which is in 72 days.
How were Theraclion SA’s earnings last quarter?
Theraclion SA released its earnings results on Apr 16, 2026. The company reported -€0.053 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Theraclion SA overvalued?
According to Wall Street analysts Theraclion SA’s price is currently Overvalued.
Does Theraclion SA pay dividends?
Theraclion SA does not currently pay dividends.
What is Theraclion SA’s EPS estimate?
Theraclion SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theraclion SA have?
Theraclion SA has 73,123,314 shares outstanding.
What happened to Theraclion SA’s price movement after its last earnings report?
Theraclion SA reported an EPS of -€0.053 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.427%.
Which hedge fund is a major shareholder of Theraclion SA?
Currently, no hedge funds are holding shares in FR:ALTHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theraclion SA
Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a robotic, non-surgical echotherapy system designed for addressing varicose veins, and ECHOPULSE, a similar robotic, non-invasive solution for treating thyroid nodules and breast fibroadenoma. Furthermore, the company provides EPack, a disposable component used during procedures to protect the patient's skin and enhance image clarity.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Novacyt
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―